Histopathology of the Central and Peripheral Nervous System for Neurotoxicity Studies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Histopathology of the Central and Peripheral Nervous System for Neurotoxicity Studies

Histology of the Central and Peripheral Nervous System for Neurotoxicity Studies

CELL & GENE | RNA | BIOLOGICS

  • Precision Neuropathology for Advanced Therapeutic Modalities.*

Evaluating the safety of novel therapeutics targeting the central nervous system (CNS) requires specialized neuropathology capabilities. Standard toxicology assessments are insufficient for characterizing the complex interactions between advanced vectors and neural tissues. This service provides GxP-compliant histological analysis of the CNS and peripheral nervous system (PNS), delivering definitive data on neurotoxicity and target engagement to support IND submissions for complex biologics.

What specific CNS and PNS tissues can you process for neurotoxicity studies?
We routinely process a comprehensive range of neural tissues, including multiple brain regions (cortex, hippocampus, cerebellum, brainstem), spinal cord at various levels, dorsal root ganglia (DRG), and peripheral nerves such as the sciatic nerve. Our protocols are optimized for perfusion fixation and specialized embedding techniques to ensure maximal tissue integrity for analysis.
How do you ensure GxP compliance in neuropathology assessments?
All studies are conducted within a robust GxP framework. This includes protocol-driven procedures performed by board-certified veterinary pathologists, validated Standard Operating Procedures (SOPs) for all technical phases, the use of qualified digital pathology platforms for analysis and archival, and oversight by our independent Quality Assurance unit.
What is the typical turnaround time for a standard neurotoxicity histology panel?
While timelines are study-dependent, our streamlined workflows and dedicated resources are structured to support an accelerated 18-24 month IND timeline. We provide clear project milestones from tissue receipt to final report delivery to ensure alignment with your development schedule.
Do you offer quantitative image analysis for neuropathology?
Yes. We supplement traditional qualitative pathology reads with validated quantitative image analysis algorithms. This allows for objective measurement of key endpoints such as neuronal counts, glial cell activation (astrocytosis and microgliosis), myelin sheath integrity, and lesion scoring.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

Specialized Histology for CNS-Targeted Therapeutics

Assessing neurotoxicity for novel biological entities requires histological techniques that can differentiate therapeutic effects from adverse findings. The unique cellular architecture of the brain and spinal cord, protected by the blood-brain barrier, presents distinct challenges for both delivery and safety evaluation. Our pathology services are designed to address these complexities directly.

We provide a full suite of neuropathology services from our >100,000 sq ft facility, including:

  • Optimized Tissue Processing: Expertise in perfusion fixation, vibratome sectioning, and both paraffin and cryo-embedding to preserve delicate neural structures.

  • Advanced Staining & Immunohistochemistry (IHC): A comprehensive panel of routine (H&E), special (Luxol Fast Blue for myelin), and IHC stains to identify specific cell types (NeuN for neurons, GFAP for astrocytes, Iba1 for microglia) and assess cellular responses.

  • Board-Certified Pathologist Interpretation: All tissue evaluations are performed by experienced, board-certified veterinary pathologists with deep expertise in identifying subtle, treatment-related changes in the nervous system.

Correlating Histology with Vector Biodistribution

A key objective in preclinical development is to correlate histological findings with vector activity. For instance, studies exploring direct delivery to the cerebrospinal fluid have shown that this route can be a viable platform for treating CNS disease, evidenced by the resolution of brain lesions (PMID: 27510804). Our role is to provide the definitive microscopic evidence that confirms such outcomes. By integrating pathology data with biodistribution and biomarker results, we build a comprehensive safety and efficacy profile.

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

IND-Enabling Neurotoxicity Data Packages

The final output of any neurotoxicity study is a data package robust enough to support regulatory submission. Our approach is built to generate IND-enabling reports that clearly articulate all study findings. This ensures that pathological findings are clearly communicated, supporting timely interpretation of preclinical readouts and informing subsequent development milestones. This commitment to quality and scientific rigor has supported our clients in achieving a 100% IND success rate since 2019. (The Franklin Biolabs brand was launched in 2024, building on this established operational history).

All in vivo research is conducted in strict accordance with our Animal Welfare policies, which fully embrace the 3Rs principles (Reduction, Refinement, and Replacement). Our programs are overseen by AAALAC and USDA regulatory standards to ensure the highest level of ethical and humane treatment.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities